undamentalytics Newsletter
Sign in

West Pharmaceutical Services cash flow statement

In fiscal 2025, West Pharmaceutical Services's operations generated $755m of cash; it spent $286m on capital projects, leaving free cash flow of $469m. It returned $61.2m in dividends and $134m through buybacks.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Cash from operations138138131187221183212219263289367473584724777653755655
Depreciation and amortisation687376778590909197104103109122121137155171184
Stock-based pay888162119302016152434382423192429
Capital spending1057195131152112132170131105126174253285362377286201
Free cash flow3367355669718149133184241298331439415276469453
Free cash flow after stock pay2559274147525130116169216264293416391258445425
Dividends paid202223252729323639424548515457596163
Share buybacks1245—0052747183116137203438561134685

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: WST vs XRAYNVST vs WSTALGN vs WSTCOO vs WST

More: Health Care Supplies stocks compared, Health Care sector, rankings of US companies

Figures from West Pharmaceutical Services's SEC filings (10-K and 10-Q), retrieved October 30, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to West Pharmaceutical Services.